Monday, May 22, 2017 9:23:15 AM
"National Agency for Food and Drug Administration and Control (“NAFDAC”) approval paves way for Immune Therapeutics’ first significant revenue channel
Immune Therapeutics’ goal to capture 20% share of Nigeria’s billion-dollar HIV/AIDS treatment market
Lodonal to represent a significant “breakthrough” as the first affordable, non-toxic adjunct therapy for HIV/AIDS
Company expected to strengthen management team to spearhead commercialization throughout Africa
With initial contracts expected shortly, company on-track to meet guidance of achieving profitability by end of current fiscal year"
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM